Respiratory Pharmacology Group, Pharmacology and Toxicology, National Heart and Lung Institute, Faculty of Medicine, London, UK.
Thorax. 2012 Jan;67(1):19-25. doi: 10.1136/thoraxjnl-2011-200365. Epub 2011 Aug 13.
In allergic asthma, exposure to relevant antigens leads to an early asthmatic response (EAR) followed, in certain subjects, by a late asthmatic response (LAR). Although many subjects with asthma consider LAR to be one of the defining symptoms of their disease, and despite its widespread use in the clinical assessment of new therapeutic entities, the mechanism underlying the LAR remains unclear.
A study was undertaken using ovalbumin-sensitised and challenged Brown Norway rat and C57BL/6J mouse models which recapitulate phenotypic features of allergic asthma including the LAR and its susceptibility to clinically effective agents.
In conscious animals an EAR was followed by a LAR. The LAR was subjectively evidenced by audible (wheeze) and visual signs of respiratory distress associated with quantifiable changes in non-invasive lung function assessment. Treatments that attenuated the EAR failed to impact on the LAR and, while anaesthesia did not impact on EAR, it abolished LAR. A key role for airway sensory neuronal reflexes in the LAR was therefore hypothesised, which was confirmed by the blockade observed after administration of ruthenium red (non-selective cation channel blocker), HC-030031 (TRPA1 inhibitor) and tiotropium bromide (anticholinergic) but not JNJ-17203212 (TRPV1 inhibitor).
These results suggest that LAR involves the following processes: allergen challenge triggering airway sensory nerves via the activation of TRPA1 channels which initiates a central reflex event leading to a parasympathetic cholinergic constrictor response. These data are supported by recent clinical trials suggesting that an anticholinergic agent improved symptoms and lung function in patients with asthma.
在过敏性哮喘中,暴露于相关抗原会导致早期哮喘反应(EAR),随后在某些患者中会出现晚期哮喘反应(LAR)。尽管许多哮喘患者认为 LAR 是其疾病的定义症状之一,并且尽管它在新治疗实体的临床评估中广泛使用,但 LAR 的机制仍不清楚。
本研究采用卵清蛋白致敏和攻击的 Brown Norway 大鼠和 C57BL/6J 小鼠模型进行,这些模型重现了过敏性哮喘的表型特征,包括 LAR 及其对临床有效药物的敏感性。
在清醒动物中,EAR 后出现 LAR。LAR 主观上表现为可听见的(喘息)和呼吸窘迫的可见迹象,与无创性肺功能评估中的可量化变化相关。减轻 EAR 的治疗方法未能影响 LAR,而麻醉对 EAR 没有影响,但消除了 LAR。因此,假设气道感觉神经元反射在 LAR 中起关键作用,这一假设得到了以下观察结果的证实:给予钌红(非选择性阳离子通道阻滞剂)、HC-030031(TRPA1 抑制剂)和噻托溴铵(抗胆碱能药)后观察到阻滞,但 JNJ-17203212(TRPV1 抑制剂)则没有。
这些结果表明,LAR 涉及以下过程:过敏原挑战通过激活 TRPA1 通道触发气道感觉神经,从而引发中枢反射事件,导致副交感神经胆碱能收缩反应。这些数据得到了最近临床试验的支持,这些试验表明抗胆碱能药物改善了哮喘患者的症状和肺功能。